Johnson & Johnson pulls out of HIV phase III trial
Johnson & Johnson stopped the phase III trial of its global HIV vaccine trial after it found that the regimen was ineffective in.
Drugs
Pharma
Drugs
Pharma
India bolsters regulators to brace global competition
India is bolstering its regulatory bodies to global standards to become a world leader in drug discovery and innovative medical devices, a minister.
Climate
Health
Adani Green to acquire Essel Saurya in an all-cash deal
Adani Renewable Energy Holding Two, a wholly-owned subsidiary of Adani Green Energy, announced it has entered into a binding term sheet to acquire.
Drugs
Pharma
Glenmark’s heart failure treatment drug makes India debut
Glenmark Pharmaceuticals, an Indian multinational firm, has introduced its heart failure drug in the country, according to a company statement.
Drugs
Pharma
US regulatory nod for Lupin’s HIV drug in the works
Pharma major Lupin has received a ‘tentative approval’, from the United States Food and Drug Administration (FDA), to market medicines used to treat.
Health
Medical
Scientists find the reason behind prolonged loss of smell after Covid infection
New research led by Duke researchers says that the SARS Cov-2 virus can make the immune system attack the nerve cells in the.
Health
Medical
Uncategorized
Skipping meals may save time but will cost you in health and mortality
Skipping meals and eating meals too closely together may be linked with increased cardiovascular or mortality, researchers report.
Drugs
Pharma
USFDA grants ‘tentative approval’ to Zydus’ mental health drug
The USFDA has granted Zydus Lifesciences Limited ‘tentative approval’ to market Levomilnacipran extended-release capsules in 20 mg, 40 mg, 80 mg, and 120.
Health
Pharma
Uncategorized
Domestic formulations to aid pharma growth: ICICI Direct
The Indian pharmaceutical industry is expected to witness “decent growth” during the three-month period through 31 March 2023, mainly led by continued traction.
Drugs
Pharma
Eiasi files market authorization for Alzheimer’s drug in Japan
Eiasi Co., a Japanese pharmaceutical company, has submitted a marketing authorization application for a drug, lacanemab, to treat Alzheimer's disease.